Cargando…

Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial

BACKGROUND: The Stockholm III trial randomly assigned 840 patients to short-course radiotherapy of 5 × 5 Gy with surgery within 1 week (SRT), short-course radiotherapy of 5 × 5 Gy with surgery after 4–8 weeks (SRT-delay), or long-course radiotherapy of 25 × 2 Gy with surgery after 4–8 weeks (LRT-del...

Descripción completa

Detalles Bibliográficos
Autores principales: Erlandsson, Johan, Fuentes, Stina, Radu, Calin, Frödin, Jan-Erik, Johansson, Hemming, Brandberg, Yvonne, Holm, Torbjörn, Glimelius, Bengt, Martling, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765334/
https://www.ncbi.nlm.nih.gov/pubmed/35040942
http://dx.doi.org/10.1093/bjsopen/zrab137
_version_ 1784634315235131392
author Erlandsson, Johan
Fuentes, Stina
Radu, Calin
Frödin, Jan-Erik
Johansson, Hemming
Brandberg, Yvonne
Holm, Torbjörn
Glimelius, Bengt
Martling, Anna
author_facet Erlandsson, Johan
Fuentes, Stina
Radu, Calin
Frödin, Jan-Erik
Johansson, Hemming
Brandberg, Yvonne
Holm, Torbjörn
Glimelius, Bengt
Martling, Anna
author_sort Erlandsson, Johan
collection PubMed
description BACKGROUND: The Stockholm III trial randomly assigned 840 patients to short-course radiotherapy of 5 × 5 Gy with surgery within 1 week (SRT), short-course radiotherapy of 5 × 5 Gy with surgery after 4–8 weeks (SRT-delay), or long-course radiotherapy of 25 × 2 Gy with surgery after 4–8 weeks (LRT-delay). This study details the long-term oncological outcomes and health-related quality of life (HRQoL). METHODS: Patients with biopsy-proven resectable adenocarcinoma of the rectum were included. Primary outcome was time to local recurrence (LR), and secondary endpoints were distant metastases (DMs), overall survival (OS), recurrence-free survival (RFS), and HRQoL. Patients were analysed in a three-arm randomization and a short-course radiotherapy comparison. RESULTS: From 1998 to 2013, 357, 355, and 128 patients were randomized to the SRT, SRT-delay, and LRT-delay groups respectively. Median follow-up time was 5.7 (range 5.3–7.6) years. Comparing patients in the three-arm randomization, the incidence of LR was three of 129 patients, four of 128, and seven of 128, and DM 31 of 129 patients, 38 of 128, and 38 of 128 in the SRT, SRT-delay, and LRT-delay groups respectively. In the short-course radiotherapy comparison, the incidence of LR was 11 of 357 patients and 13 of 355, and DM 88 of 357 patients and 82 of 355 in the SRT and SRT-delay groups respectively. No comparisons showed statistically significant differences. Median OS was 8.1 (range 6.9–11.2), 10.3 (range 8.2–12.8), and 10.5 (range 7.0–11.3) years after SRT, SRT-delay, and LRT-delay respectively. Median OS was 8.1 (range 7.2–10.0) years after SRT and 10.2 (range 8.5–11.7) years after SRT-delay. There were no statistically significant differences in HRQoL. CONCLUSION: After a follow-up of 5 years, delaying surgery for 4–8 weeks after radiotherapy treatment with 5 × 5 Gy was oncologically safe. Long-term HRQoL was similar among the treatment arms. TRIAL REGISTRATION NUMBER: NTC00904813
format Online
Article
Text
id pubmed-8765334
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87653342022-01-19 Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial Erlandsson, Johan Fuentes, Stina Radu, Calin Frödin, Jan-Erik Johansson, Hemming Brandberg, Yvonne Holm, Torbjörn Glimelius, Bengt Martling, Anna BJS Open Original Article BACKGROUND: The Stockholm III trial randomly assigned 840 patients to short-course radiotherapy of 5 × 5 Gy with surgery within 1 week (SRT), short-course radiotherapy of 5 × 5 Gy with surgery after 4–8 weeks (SRT-delay), or long-course radiotherapy of 25 × 2 Gy with surgery after 4–8 weeks (LRT-delay). This study details the long-term oncological outcomes and health-related quality of life (HRQoL). METHODS: Patients with biopsy-proven resectable adenocarcinoma of the rectum were included. Primary outcome was time to local recurrence (LR), and secondary endpoints were distant metastases (DMs), overall survival (OS), recurrence-free survival (RFS), and HRQoL. Patients were analysed in a three-arm randomization and a short-course radiotherapy comparison. RESULTS: From 1998 to 2013, 357, 355, and 128 patients were randomized to the SRT, SRT-delay, and LRT-delay groups respectively. Median follow-up time was 5.7 (range 5.3–7.6) years. Comparing patients in the three-arm randomization, the incidence of LR was three of 129 patients, four of 128, and seven of 128, and DM 31 of 129 patients, 38 of 128, and 38 of 128 in the SRT, SRT-delay, and LRT-delay groups respectively. In the short-course radiotherapy comparison, the incidence of LR was 11 of 357 patients and 13 of 355, and DM 88 of 357 patients and 82 of 355 in the SRT and SRT-delay groups respectively. No comparisons showed statistically significant differences. Median OS was 8.1 (range 6.9–11.2), 10.3 (range 8.2–12.8), and 10.5 (range 7.0–11.3) years after SRT, SRT-delay, and LRT-delay respectively. Median OS was 8.1 (range 7.2–10.0) years after SRT and 10.2 (range 8.5–11.7) years after SRT-delay. There were no statistically significant differences in HRQoL. CONCLUSION: After a follow-up of 5 years, delaying surgery for 4–8 weeks after radiotherapy treatment with 5 × 5 Gy was oncologically safe. Long-term HRQoL was similar among the treatment arms. TRIAL REGISTRATION NUMBER: NTC00904813 Oxford University Press 2022-01-18 /pmc/articles/PMC8765334/ /pubmed/35040942 http://dx.doi.org/10.1093/bjsopen/zrab137 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Erlandsson, Johan
Fuentes, Stina
Radu, Calin
Frödin, Jan-Erik
Johansson, Hemming
Brandberg, Yvonne
Holm, Torbjörn
Glimelius, Bengt
Martling, Anna
Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial
title Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial
title_full Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial
title_fullStr Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial
title_full_unstemmed Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial
title_short Radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the Stockholm III trial
title_sort radiotherapy regimens for rectal cancer: long-term outcomes and health-related quality of life in the stockholm iii trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8765334/
https://www.ncbi.nlm.nih.gov/pubmed/35040942
http://dx.doi.org/10.1093/bjsopen/zrab137
work_keys_str_mv AT erlandssonjohan radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT fuentesstina radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT raducalin radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT frodinjanerik radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT johanssonhemming radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT brandbergyvonne radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT holmtorbjorn radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT glimeliusbengt radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial
AT martlinganna radiotherapyregimensforrectalcancerlongtermoutcomesandhealthrelatedqualityoflifeinthestockholmiiitrial